Lead Product(s): Tapentadol
Therapeutic Area: Neurology
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Collegium Pharmaceutical
Deal Size: $375.0 million Upfront Cash: $375.0 million
Deal Type: Agreement February 06, 2020
Assertio Therapeutics has entered into a definitive agreement with Collegium Pharmaceutical, Inc. under which Collegium will acquire the NUCYNTA® franchise of products from the Company.